CIBC Private Wealth Group LLC Sells 212,537 Shares of IQVIA Holdings Inc. (NYSE:IQV)

CIBC Private Wealth Group LLC lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 15.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 1,186,464 shares of the medical research company’s stock after selling 212,537 shares during the period. CIBC Private Wealth Group LLC’s holdings in IQVIA were worth $242,418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently bought and sold shares of IQV. Private Trust Co. NA lifted its holdings in IQVIA by 10.7% during the 3rd quarter. Private Trust Co. NA now owns 485 shares of the medical research company’s stock valued at $115,000 after purchasing an additional 47 shares during the last quarter. Pine Valley Investments Ltd Liability Co increased its holdings in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company’s stock worth $2,247,000 after buying an additional 50 shares in the last quarter. Howard Capital Management Inc. boosted its holdings in shares of IQVIA by 4.9% in the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock worth $225,000 after acquiring an additional 54 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in IQVIA by 1.0% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 5,434 shares of the medical research company’s stock worth $1,068,000 after acquiring an additional 56 shares during the last quarter. Finally, Cypress Wealth Services LLC increased its holdings in IQVIA by 4.8% during the 4th quarter. Cypress Wealth Services LLC now owns 1,243 shares of the medical research company’s stock valued at $244,000 after purchasing an additional 57 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on IQV shares. Stifel Nicolaus reduced their price objective on IQVIA from $273.00 to $261.00 and set a “buy” rating on the stock in a research note on Friday, February 7th. Stephens began coverage on shares of IQVIA in a research report on Friday, December 20th. They set an “overweight” rating and a $250.00 price target on the stock. UBS Group lowered their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research report on Friday, February 7th. Citigroup reduced their target price on shares of IQVIA from $225.00 to $210.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 4th. Finally, Truist Financial reissued a “buy” rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $249.05.

IQVIA Stock Down 1.2 %

IQVIA stock opened at $177.27 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $176.03 and a fifty-two week high of $253.84. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market capitalization of $31.25 billion, a price-to-earnings ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The company’s 50 day simple moving average is $193.15 and its 200 day simple moving average is $206.27.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. As a group, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.